Kaposi Sarcoma – Pipeline Review, H1 2017

Global Markets Direct’s, ‘Kaposi Sarcoma – Pipeline Review, H1 2017’, provides an overview of the Kaposi Sarcoma pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Kaposi Sarcoma, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Kaposi Sarcoma and features dormant and discontinued projects.

Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

– The report provides a snapshot of the global therapeutic landscape of Kaposi Sarcoma

– The report reviews pipeline therapeutics for Kaposi Sarcoma by companies and universities/research institutes based on information derived from company and industry-specific sources

– The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages

– The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities

– The report reviews key players involved Kaposi Sarcoma therapeutics and enlists all their major and minor projects

– The report assesses Kaposi Sarcoma therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type

– The report summarizes all the dormant and discontinued pipeline projects

– The report reviews latest news related to pipeline therapeutics for Kaposi Sarcoma

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies

- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage

- Identify and understand important and diverse types of therapeutics under development for Kaposi Sarcoma

- Identify potential new clients or partners in the target demographic

- Develop strategic initiatives by understanding the focus areas of leading companies

- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics

- Devise corrective measures for pipeline projects by understanding Kaposi Sarcoma pipeline depth and focus of Indication therapeutics

- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope

- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline

Companies mentioned

Aphios Corp

Cannabis Science Inc

CytRx Corp

LATITUDE Pharmaceuticals Inc

RedHill Biopharma Ltd

Tumorend LLC

VasGene Therapeutics Inc

Table of Contents

Table of Contents

List of Tables

List of Figures

Introduction

Global Markets Direct Report Coverage

Kaposi Sarcoma - Overview

Kaposi Sarcoma - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Kaposi Sarcoma - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Kaposi Sarcoma - Companies Involved in Therapeutics Development

Aphios Corp

Cannabis Science Inc

CytRx Corp

LATITUDE Pharmaceuticals Inc

RedHill Biopharma Ltd

Tumorend LLC

VasGene Therapeutics Inc

Kaposi Sarcoma - Drug Profiles

ABC-294640 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

aldoxorubicin hydrochloride - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CM-101 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

CSTATI-1 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Dermos - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

doxorubicin - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon alfa-2a - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

interferon alfa-2b - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

paclitaxel - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Synthetic Peptide to Inhibit HAUSP for Lymphoma and Kaposi Sarcoma - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

TLD-208 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Vas-01 - Drug Profile

Product Description

Mechanism Of Action

R&D Progress

Kaposi Sarcoma - Dormant Projects

Kaposi Sarcoma - Discontinued Products

Kaposi Sarcoma - Product Development Milestones

Featured News & Press Releases

Jun 06, 2016: CytRx Presents Updated Aldoxorubicin Clinical Trial Results at the 2016 American Society of Clinical Oncology Annual Meeting

May 26, 2016: $1.8 Million Fast-Track NIH SBIR Grant for Manocept Immunotherapeutics Evaluation in Kaposi’s Sarcoma Awarded to Navidea

May 03, 2016: Navidea and Macrophage Therapeutics to Provide Development Program Update

Apr 20, 2016: CytRx to Present Updated Aldoxorubicin Clinical Trial Data at the American Society of Clinical Oncology Annual Meeting in June 2016

Sep 03, 2015: Navidea Awarded $1.8M Fast Track NIH SBIR Grant for Evaluation of a Manocept Agent in Kaposi’s Sarcoma

Jul 02, 2015: Macrophage Therapeutics Reports Data Demonstrating a Manocept Drug Conjugate Induces Apoptosis in CD206 Positive Kaposi’s Sarcoma and Tumor Associated Macrophages

Jun 29, 2015: CytRx Announces Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma

Jan 20, 2015: CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials Permitting Immediate Enrollment of New Patients

Jan 08, 2015: CytRx Announces Positive Interim Phase 2 Aldoxorubicin Results as a Treatment for HIV-Related Kaposi's Sarcoma

Jan 23, 2014: CytRx Initiates Phase 2 Clinical Trial with Aldoxorubicin for First-Line Treatment of AIDS-Related Kaposi’s Sarcoma

Apr 26, 2013: Cannabis Science Announces Preclinical Development Program For CS-TATI-I

Nov 12, 2012: Beth Israel Deaconess Medical Center, Harvard Medical School Study Confirms Cannabis Science's Approach To Development Of CS-TATI-1 To Inhibit Kaposi Sarcoma

Sep 24, 2012: Cannabis Science Initiates Preclinical Investigation Of CS-TATI-1 For European Studies For Squamous/Basal Cell Carcinomas And Kaposi’s Sarcoma

Aug 13, 2012: CBIS Initiates GMP Development Plan For CS-TATI-1

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

List of Tables

Number of Products under Development for Kaposi Sarcoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products under Development by Universities/Institutes, H1 2017

Products under Development by Companies, H1 2017

Products under Development by Universities/Institutes, H1 2017

Number of Products by Stage and Target, H1 2017

Number of Products by Stage and Mechanism of Action, H1 2017

Number of Products by Stage and Route of Administration, H1 2017

Number of Products by Stage and Molecule Type, H1 2017

Kaposi Sarcoma – Pipeline by Aphios Corp, H1 2017

Kaposi Sarcoma – Pipeline by Cannabis Science Inc, H1 2017

Kaposi Sarcoma – Pipeline by CytRx Corp, H1 2017

Kaposi Sarcoma – Pipeline by LATITUDE Pharmaceuticals Inc, H1 2017

Kaposi Sarcoma – Pipeline by RedHill Biopharma Ltd, H1 2017

Kaposi Sarcoma – Pipeline by Tumorend LLC, H1 2017

Kaposi Sarcoma – Pipeline by VasGene Therapeutics Inc, H1 2017

Kaposi Sarcoma – Dormant Projects, H1 2017

Kaposi Sarcoma – Dormant Projects, H1 2017 (Contd..1), H1 2017

Kaposi Sarcoma – Discontinued Products, H1 2017

List of Figures

List of Figures

Number of Products under Development for Kaposi Sarcoma, H1 2017

Number of Products under Development by Companies, H1 2017

Number of Products by Top 10 Targets, H1 2017

Number of Products by Stage and Top 10 Targets, H1 2017

Number of Products by Top 10 Mechanism of Actions, H1 2017

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2017

Number of Products by Routes of Administration, H1 2017

Number of Products by Stage and Routes of Administration, H1 2017

Number of Products by Molecule Types, H1 2017

Number of Products by Stage and Molecule Types, H1 2017

    Pricing

Discounts available for multiple purchases.

reportstore@globalmarketsdirect.com
+44 20 7947 2745

Saved reports